Navigation Links
Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes
Date:8/30/2009

I SEPIA-ACS1/ TIMI-42 study randomized 3241 patients from 36 countries in 6 treatment arms. The study assessed the efficacy and safety of five different doses of otamixaban versus the standard unfractionated heparin plus Glycoprotein IIb/IIIa inhibitor (eptifibatide), on background of standard dual antiplatelet therapy, in patients with high-risk non-ST-elevation acute coronary syndromes. SEPIA-ACS1 study showed that otamixaban displayed clinically meaningful activity on the primary endpoint from the threshold dose of 0.070 mg/kg/h, the second tested dose, with a consistent antithrombotic effect up to the 5th highest tested dosage. The lowest studied dosage was prematurely stopped due to insufficient activity, based on recommendation by an independent data monitoring board. Moreover a combined analysis of the intermediate doses (0.105 and 0.140 mg/kg/h) of otamixaban arms showed that otamixaban reduced by approximately 46 percent (p=0.0198) the risk of the composite of death or a second myocardial infarction, a predefined study secondary efficacy endpoint.

The potent antithrombotic effect of otamixaban was also accompanied with a dose-dependent bleeding profile. Combined intermediate otamixaban dosages showed a safety profile not statistically different with regard to TIMI major or minor bleeding through 7 days, in comparison to UFH and GPIIb/IIIa inhibitor comparator (RR 1.20, 95% CI 0.64-2.27, p=0.5634).

"The SEPIA-ACS1 trial is providing very encouraging results for a new and more effective treatment approach," said Marc Cluzel, MD Senior Vice President Research and Development Sanofi-aventis. "We aim, on the basis of these findings to address through our development program remaining patients', practionners' and payers' needs for management of ACS."

Acute Coronary Syndromes is a general term used to regroup clinical symptoms related to acute myocardial ischemia. ACS represents an area of important
'/>"/>

SOURCE Sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of PLAVIX(R) in Acute Coronary Syndrome Patients Undergoing Angioplasty
2. Gen-Probe Begins U.S. Clinical Study of PROGENSA(R) PCA3 Assay, New Molecular Test to Help Assess Prostate Cancer Risk
3. Lurasidone Demonstrated Efficacy in Treating Patients With Schizophrenia in Pivotal Phase 3 Study
4. Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study
5. CardioDx Completes Validation Study of First-Of-Its-Kind Genomic Test for Coronary Artery Disease
6. R-Tech Ueno Completes Subject Enrollment in Phase 2 Clinical Study of 0.15% UF-021
7. WorldHeart Receives US Clinical Study Approval for the Levacor(TM) VAD
8. Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinsons Disease
9. Study Links Fetal Fibronectin Testing with Changes in Management Decisions for Symptomatic and Asymptomatic Women at Risk for Preterm Birth
10. Study of Lacrisert(R) Dry Eye Insert Published in The Ocular Surface
11. Amarex Clinical Research Selects OmniComm Systems to Provide eClinical Solutions for Phase III Medical Device Study and Joins OmniComms CRO Preferred Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... , April 24, 2015   Vestagen Technical Textiles, ... VESTEX ® , has recently received two notable innovation ... global competition that recognizes innovations with potential to create ... last night in New York City ... Material Science "Protection & Safety" category. The awards honor ...
(Date:4/24/2015)... Research and Markets ( http://www.researchandmarkets.com/research/pmbmv2/global_biobanking ) ... Market 2015-2019" report to their offering. ... at a CAGR of 7.07% over the period 2014-2019 ... into two segments: Equipment and Consumables. This report covers ... Global Biobanking market for the period 2015-2019. ...
(Date:4/24/2015)... EAST HANOVER, N.J. , April 24, 2015  Novartis ... diversity for the second year in a row on the ... the results of its 2015 Top 50 Companies for Diversity ... New York, NY . NPC also ranked second on ... on the Top 10 Companies for Employee Resource Groups list. ...
Breaking Medicine Technology:VESTEX Wins Innovation Honors from Edison Awards & Apparel Magazine 2VESTEX Wins Innovation Honors from Edison Awards & Apparel Magazine 3Global Biobanking Market Report 2015-2019 - Increase in Strategic Collaborations with Beckman Coulter, Tecan & Thermo Fischer Scientific Dominating 2Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list 2Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list 3Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list 4
(Date:4/25/2015)... The impact of the Trivedi Master ... of the public and is likely to cause further, ... and June. From March 21st to March 31st, ... "Special Prayers." More than 600 people participated in the ... and have reported intense experiences that they attest have ...
(Date:4/25/2015)... New York New York (PRWEB) April 25, 2015 ... announce that Dr. Jerry Blaivas has been chosen by the ... Award for his contributions to medicine in the field of ... as the best in his speciality, Genito-Urinary diseases. He ... medicine, specifically in the field of urology. Not only ...
(Date:4/24/2015)... Irvine, CA (PRWEB) April 24, 2015 Bird ... industrial and residential applications now offers a complete line of ... flu to poultry farms. , New Flu Strains Threaten Pacific, ... 22, 2015 USDA post , a number of highly ... bird paths. The disease is often spread when wild birds ...
(Date:4/24/2015)... 2015 Ryadon is a leading manufacturer ... capabilities and services to complement any custom hardware requirements ... Program will be offered on all heavy duty drawer ... Receive 10% discount - Order 20+: Receive 20% discount ... Slides Products, Furniture ,Drawer ...
(Date:4/24/2015)... 2015 The 1975 have had ... across the globe to theaters, festivals and TV performances. Now ... partnered with their label, Dirty Hit Records, to provide clean ... the newly launched Cadence & Cause website, this ... on vinyl and a signed photo card. Entries from ...
Breaking Medicine News(10 mins):Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 2Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 3Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 2Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 3Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 2Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 3Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 4Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 2Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 3Health News:Internationally Recognized British Indie Rock Outfit The 1975 Partner with Cadence & Cause to Provide Clean Drinking Water to Those in Need 2
... has been a considerable fall in the donations towards providing ... United Nations (UN). The December 2005 contributions were not even ... ,Jan Vandemoortele, the UN Resident Coordinator has appealed to ... pledged by them. A special envoy will be appointed by ...
... can be manipulated to get relief from chronic discomfort, according ... ,As many as eight patients were taught to reduce ... // mental exercises. Standard therapy has not been very ... opened through the results of the research. People can be ...
... Bone marrow disorder Myelodysplastic Syndrome (MDS), treated with 500 ... found to improve the hemoglobin content in 70% of ... Biotech, which conducted a Phase II trial with 200 ... of Aranesp every three weeks. MDS is a pre-leukemia ...
... produced a new vaccine Gardasil which is found to ... infection from two strains of Human Papilloma Virus which ... the new vaccine Gardasil is being conducted by the ... the most common cancers affective the women reproductive system, ...
... Yale study recommends that oncology researchers consider the 100-year-old ... as a major reason cancer metastasizes.// ,'Cancer ... to white blood cells known as macrophages, including the ... and to form a new blood supply,' said lead ...
... to deal with a nearly certain outbreak of a bird flu ... EU medical expert.// ,Professor Johan Giesecke of the ... chief veterinary and medical officers of the 25 EU nations met ... ,'It might not happen tomorrow, or in the next few ...
Cached Medicine News:Health News:EU medical chief says Europe ready for bird flu 2
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
D-Stat Radial is a dry version of the D-Stat together with a compression band, and is designed for the control of surface bleeding from vascular access sites, including the sites on the radial artery...
... engineered to close arteriotomies with ease ... with a simple trigger actvated mechanism, ... deliver sheath gently locks onto the ... the site before, during, and after ...
... is composed of an absorbable collagen sponge ... connected by an absorbable self-tightening suture. The ... its two primary components, the anchor and ... primarily through mechanical means and is supplemented ...
Medicine Products: